Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018144514 - TNF SUPERFAMILY FUSION POLYPEPTIDES

Publication Number WO/2018/144514
Publication Date 09.08.2018
International Application No. PCT/US2018/016100
International Filing Date 31.01.2018
IPC
C07K 14/525 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
525Tumour necrosis factor (TNF)
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
CPC
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 14/70575
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
C07K 14/70578
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
C07K 2319/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applicants
  • MERRIMACK PHARMACEUTICALS, INC. [US]/[US]
Inventors
  • SCHOEBERL, Birgit M.
  • TAM, Eric M.
Agents
  • BOTT, Cynthia M.
Priority Data
62/453,31301.02.2017US
62/453,33801.02.2017US
62/453,35401.02.2017US
62/453,35701.02.2017US
62/453,37301.02.2017US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) TNF SUPERFAMILY FUSION POLYPEPTIDES
(FR) POLYPEPTIDES DE FUSION DE LA SUPERFAMILLE DU TNF
Abstract
(EN) Engineered 4-1BBL polypeptides and Fc-4-1BBL fusion polypeptides and methods for using such polypeptides and compositions to treat 4-1BB-related disorders (e.g., cancer). Engineered CD70 polypeptides and Fc-CD70 fusion polypeptides and methods for using such polypeptides and compositions to treat CD70-related disorders (e.g., cancer). Engineered GITRL polypeptides and Fc-GITRL fusion polypeptides and methods for using such polypeptides and compositions to treat GITRL-related disorders (e.g., cancer). Engineered OX40L polypeptides and Fc-OX40L fusion polypeptides and methods for using such polypeptides and compositions to treat OX40L-related disorders (e.g., cancer). Engineered CD40L polypeptides and Fc-CD40L fusion and methods for using such polypeptides and compositions to treat CD40L-related disorders (e.g., cancer). Engineered LIGHT polypeptides and Fc-LIGHT fusion polypeptides and methods for using such polypeptides and compositions to treat LIGHT-related disorders (e.g., cancer).
(FR) L'invention concerne des polypeptides 4-1BBL modifiés et des polypeptides de fusion Fc-4-1BBL, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à 4-1BB (par exemple, le cancer). L'invention concerne de plus des polypeptides CD70 modifiés et des polypeptides de fusion Fc-CD70, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à CD70 (par exemple, le cancer). L'invention concerne en outre des polypeptides GITRL modifiés et des polypeptides de fusion Fc-GITRL, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à GITRL (par exemple, le cancer). L'invention concerne également des polypeptides OX40L modifiés et des polypeptides de fusion Fc-OX40L, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à OX40L (par exemple, le cancer). L'invention concerne par ailleurs des polypeptides CD40L modifiés et des polypeptides de fusion Fc-CD40L, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés au CD40L (par exemple, le cancer). L'invention concerne de plus encore des polypeptides LIGHT modifiés et des polypeptides de fusion Fc-LIGHT, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés au LIGHT (par exemple, le cancer).
Latest bibliographic data on file with the International Bureau